Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. Chief Legal Officer Rahul Khara reported an open-market sale of 2,853 shares of common stock at an average price of $62.86 per share on February 17, 2026. According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary sale. After this transaction, Khara directly owned 52,173 shares of Disc Medicine common stock.
Disc Medicine, Inc. Chief Commercial Officer Pamela Stephenson reported an open-market sale of 5,531 shares of common stock at $62.86 per share. According to the filing, the sale was solely to cover tax withholding on vesting restricted stock units. She now holds 80,998 shares directly.
Disc Medicine, Inc. Chief Medical Officer William Jacob Savage reported an open-market sale of 3,256 shares of common stock at $62.86 per share. According to the footnote, this was a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations from vesting restricted stock units. After the sale, he directly owned 92,589 shares.
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported an open-market sale of 3,231 shares of common stock at $62.86 per share. After the transaction, he directly owns 54,324 shares. According to the footnote, the sale was solely to cover tax withholding on vesting restricted stock units and was not a discretionary trade.
Disc Medicine, Inc. Chief Executive Officer John D. Quisel reported an open‑market sale of 13,264 shares of common stock at $62.86 per share. According to the filing, this was a "sell to cover" transaction to satisfy tax withholding obligations from vesting restricted stock units and was not a discretionary trade. After the sale, Quisel directly owned 226,064 shares of Disc Medicine common stock.
IRON reporting a Form 144 notice for proposed sale of 2,853 common shares tied to RSU vesting on 02/15/2026. The filing also records prior brokered 10b5-1 sales by Rahul Khara of 6,500 shares on 01/02/2026 for $511,471.98 and 1,000 shares on 01/20/2026 for $69,740.
SAVAGE submitted a Form 144 reporting a proposed sale of 3,256 shares of common stock of the company trading on NASDAQ, tied to an RSU vesting event dated 02/15/2026. The filing also records 13,093 shares sold on 12/15/2025 for $1,194,372.44.